1DpwC8F

Recommendations

Info

Intimate Partner Violence and Elderly Abuse Title Screening for Intimate Partner Violence and Abuse of Elderly and Vulnerable Adults Population Asymptomatic women of childbearing age Elderly or vulnerable adults Recommendation Screen women for intimate partner violence (IPV), and provide or refer women who screen positive to intervention services. Grade: B No recommendation. Grade: I (Insufficient Evidence) Risk Assessment While all women are at potential risk for abuse, factors that elevate risk include young age, substance abuse, marital difficulties, and economic hardships. 44 Interventions Balance of Benefits and Harms Adequate evidence from randomized trials support a variety of interventions for women of childbearing age that can be delivered or referred by primary care, including counseling, home visits, information cards, referrals to community services, and mentoring support. Depending on the type of intervention, these services may be provided by clinicians, nurses, social workers, nonclinician mentors, or community workers. Screening and interventions for IPV in women of childbearing age are associated with moderate health improvements through the reduction of exposure to abuse, physical and mental harms, and mortality. The associated harms are deemed no greater than small. Therefore, the overall net benefit is moderate. The USPSTF was not able to estimate the magnitude of net benefit for screening all elderly or vulnerable adults (i.e., adults who are physically or mentally dysfunctional) for abuse and neglect because there were no studies on the accuracy, effectiveness, or harms of screening in this population. Other Relevant USPSTF Recommendations The USPSTF has made recommendations on screening for depression in adults and screening and counseling to reduce alcohol misuse in adults. These recommendations are available at http://www.uspreventiveservicestaskforce.org/. For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org/.
Lipid Disorders in Adults Title Screening for Lipid Disorders in Adults Population ●● ●● Men age 35 years and older Women age 45 years and older who are at increased risk for coronary heart disease (CHD) ●● ●● Men ages 20 to 35 years who are at increased risk for CHD Women ages 20 to 45 years who are at increased risk for CHD ●● ●● Men ages 20 to 35 years Women age 20 years and older who are not at increased risk for CHD Recommendation Screen for lipid disorders. Grade: A Screen for lipid disorders. Grade: B No recommendation for or against screening Grade: C 45 Risk Assessment Screening Tests Timing of Screening Interventions Balance of Benefits and Harms Other Relevant USPSTF Recommendations Consideration of lipid levels along with other risk factors allows for an accurate estimation of CHD risk. Risk factors for CHD include diabetes, history of previous CHD or atherosclerosis, family history of cardiovascular disease, tobacco use, hypertension, and obesity (body mass index ≥30 kg/m 2 ). The preferred screening tests for dyslipidemia are measuring serum lipid (total cholesterol, high-density and low-denisty lipoprotein cholesterol) levels in non-fasting or fasting samples. Abnormal screening results should be confirmed by a repeated sample on a separate occasion, and the average of both results should be used for risk assessment. The optimal interval for screening is uncertain. Reasonable options include every 5 years, shorter intervals for people who have lipid levels close to those warranting therapy, and longer intervals for those not at increased risk who have had repeatedly normal lipid levels. An age at which to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65 years. Drug therapy is usually more effective than diet alone in improving lipid profiles, but choice of treatment should consider overall risk, costs of treatment, and patient preferences. Guidelines for treating lipid disorders are available from the National Cholesterol Education Program of the National Institutes of Health (http://www.nhlbi.nih.gov/about/ncep/). The benefits of screening for and treating lipid disorders in men age 35 and older and women age 45 and older at increased risk for CHD substantially outweigh the potential harms. The benefits of screening for and treating lipid disorders in young adults at increased risk for CHD moderately outweigh the potential harms. The net benefits of screening for lipid disorders in young adults not at increased risk for CHD are not sufficient to make a general recommendation. The USPSTF has made recommendations on screening for lipid disorders in children and screening for carotid artery stenosis, coronary heart disease, high blood pressure, and peripheral arterial disease. These recommendations are available at http://www.uspreventiveservicestaskforce.org/. For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org/.
Page 1 and 2:
The Guide to Clinical Preventive Se
Page 3:
The Guide to Clinical Preventive Se
Page 7 and 8:
Preface The U.S. Preventive Service
Page 9: Selector (ePSS), available via PDA,
Page 12 and 13: Hemochromatosis, Screening.........
Page 15: Preventive Services Recommended by
Page 18 and 19: Section 1: Preventive Services Reco
Page 20 and 21: 4 13 Asymptomatic adults with susta
Page 23 and 24: Abdominal Aortic Aneurysm Title Scr
Page 25 and 26: Aspirin for the Prevention of Cardi
Page 27 and 28: Bacterial Vaginosis in Pregnancy Ti
Page 29 and 30: Bladder Cancer Title Population Rec
Page 31 and 32: Breast Cancer (Preventive Medicatio
Page 33 and 34: Breastfeeding Title Primary Care In
Page 35 and 36: Cervical Cancer Title Screening for
Page 37 and 38: Chronic Kidney Disease Title Popula
Page 39 and 40: Cognitive Impairment Title Populati
Page 41 and 42: Coronary Heart Disease (Risk Assess
Page 43 and 44: Depression in Adults Title Populati
Page 45 and 46: Falls in Older Adults Title Populat
Page 47 and 48: Genital Herpes Time Screening for G
Page 49 and 50: Glaucoma Title Population Recommend
Page 51 and 52: Healthful Diet and Physical Activit
Page 53 and 54: Hemochromatosis Title Population Re
Page 55 and 56: Hepatitis C Virus Infection Title S
Page 57 and 58: HIV Infection Title Population Reco
Page 59: Impaired Visual Acuity in Older Adu
Page 63 and 64: Menopausal Hormone Therapy Title Me
Page 65 and 66: Obesity in Adults Title Population
Page 67 and 68: Osteoporosis Title Screening for Os
Page 69 and 70: Peripheral Artery Disease Title Pop
Page 71 and 72: Sexually Transmitted Infections Tit
Page 73 and 74: Skin Cancer (Screening) Title Scree
Page 75 and 76: Syphilis (Pregnant Women) Title Pop
Page 77 and 78: Tobacco Use in Adults Title Counsel
Page 79: Vitamin Supplementation to Prevent
Page 83 and 84: Blood Lead Levels in Children and P
Page 85 and 86: Congenital Hypothyroidism Title Scr
Page 87 and 88: Gonococcal Ophthalmia Neonatorum Ti
Page 89 and 90: High Blood Pressure (Children) Titl
Page 91 and 92: Illicit and Prescription Drug Use i
Page 93 and 94: Iron Deficiency Anemia (Supplementa
Page 95 and 96: Major Depressive Disorder in Childr
Page 97 and 98: Phenylketonuria (PKU) Title Populat
Page 99 and 100: Speech and Language Delay Title Pop
Page 101: Visual Impairment in Children Ages
Page 105: Immunizations for Adults and Childr
Page 109 and 110: Topics in Progress Each USPSTF reco
Page 111:
Appendixes and Index
Page 114 and 115:
Grade Definitions What the Grades M
Page 116 and 117:
Grade Definitions Prior to May 2007
Page 118 and 119:
David Grossman, M.D., M.P.H. Center
Page 120 and 121:
Appendix C Acknowledgements AHRQ St
Page 122 and 123:
Liaisons to the USPSTF Primary care
Page 124 and 125:
The Task Force does not explicitly
Page 126 and 127:
■■ ■■ Access the Electronic
Page 128 and 129:
Appendix E More Resources AHRQ’s
Page 130 and 131:
Healthy People 2020 Healthy People
Page 133 and 134:
Index 2-hour postload plasma (see D
Page 135 and 136:
Coronary Heart Disease (Risk Assess
Page 137 and 138:
*Illicit and Prescription Drug Use
Page 139:
Syphilis Infection (Pregnant Women)
Page 143 and 144:
The U.S. Preventive Services Task F
show all

1DpwC8F

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?